Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Fish and Richardson
Chubb
Covington
QuintilesIMS
Moodys
UBS
Farmers Insurance
Teva

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SILODOSIN

« Back to Dashboard

Clinical Trials for Silodosin

Trial ID Title Status Sponsor Phase Summary
NCT00224107 A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo Completed Watson Pharmaceuticals Phase 3 A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
NCT00224120 A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo Completed Watson Pharmaceuticals Phase 3 A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
NCT00224133 The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months Completed Watson Pharmaceuticals Phase 3 A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.
NCT00359905 Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH Completed Recordati Industria Chimica e Farmaceutica S.p.A. Phase 3 A new drug for the treatment of benign prostatic hyperplasia is compared with placebo and tamsulosin (a drug belonging to the same therapeutic class) for to determine if it is safe and effective (the first phase of the study lasts approximately 18 weeks) and then is used for another 9 months to determine its long-term safety.
NCT00740779 Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Completed Watson Pharmaceuticals Phase 2 The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary objective is to compare the safety of silodosin 4 and 8 mg once daily with placebo.
NCT00793819 A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia Completed Watson Pharmaceuticals Phase 2 Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH
NCT01144949 Study of Silodosin to Facilitate Passage of Urinary Stones Completed Watson Pharmaceuticals Phase 2 The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Silodosin

Condition Name

Condition Name for Silodosin
Intervention Trials
Benign Prostatic Hyperplasia 6
Kidney Stones 2
Benign Prostatic Hyperplasia (BPH) 2
Nocturia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Silodosin
Intervention Trials
Prostatic Hyperplasia 10
Hyperplasia 9
Nephrolithiasis 3
Kidney Calculi 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Silodosin

Trials by Country

Trials by Country for Silodosin
Location Trials
United States 130
Korea, Republic of 9
Japan 2
France 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Silodosin
Location Trials
Pennsylvania 7
California 6
New York 6
Washington 5
South Carolina 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Silodosin

Clinical Trial Phase

Clinical Trial Phase for Silodosin
Clinical Trial Phase Trials
Phase 4 7
Phase 3 6
Phase 2 6
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Silodosin
Clinical Trial Phase Trials
Completed 14
Recruiting 2
Terminated 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Silodosin

Sponsor Name

Sponsor Name for Silodosin
Sponsor Trials
Watson Pharmaceuticals 6
JW Pharmaceutical 5
Kissei Pharmaceutical Co., Ltd. 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Silodosin
Sponsor Trials
Other 15
Industry 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Farmers Insurance
Deloitte
Express Scripts
Harvard Business School
Johnson and Johnson
Cipla
UBS
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.